CALiBRe Basic Results Summary

Participant Flow



Baseline Characteristics

Characteristic	Treatment Naive	Relapsed/Refractory	Overall
Cohort			
Treatment Naive	11 (100%)	0 (0%)	11 (48%)
Relapsed/Refractory	0 (0%)	12 (100%)	12 (52%)
Age (years)	66 (58, 72) [50, 85]	68 (66, 74) [59, 77]	68 (62, 73) [50, 85]
Sex			
Female	3 (27%)	0 (0%)	3 (13%)
Male	8 (73%)	12 (100%)	20 (87%)
Time since diagnosis (years)	4 (1, 5) [0, 8]	7 (6, 9) [5, 12]	6 (4, 8) [0, 12]
Unknown	2	1	3
Previous therapies	0 (0, 0) [0, 0]	2 (1, 2) [1, 2]	1 (0, 2) [0, 2]
Stage			
Progressive stage A	1 (9%)	0 (0%)	1 (5%)
Stage B	4 (36%)	5 (45%)	9 (41%)
Stage C	6 (55%)	6 (55%)	12 (55%)
Unknown	0	1	1
ECOG			
0	4 (36%)	3 (25%)	7 (30%)
1	5 (45%)	8 (67%)	13 (57%)
2	2 (18%)	1 (8%)	3 (13%)

Note: Data are n (%) for categorical, median (IQR) [range] for continuous

Outcome Measures

Primary outcome measure

Proportion of patients achieving MRD-negative remission by IWCLL criteria (depletion of CLL below 0.01% in the peripheral blood and bone marrow).

Primary outcome measure	n (%)
Patients who achieve MRD-negative remission	0 (%)

Secondary outcome measures

Best disease response: Complete Remission (CR); Complete Remission with incomplete marrow recovery (Cri) or Partial Remission (PR), to treatment within the first 6 months of treatment assessed according to the IWCLL Response Criteria.

Best Response	n (%)
Partial Remission (PR)	9 (39%)
Partial Remission with lymphocytosis	4 (17%)
Stable disease	7 (30%)
Unable to assess	1 (4%)
Discontinued before month 1 assessment due to safety measure	2 (9%)
Overall	23 (100%)

1 and 2 year progression free survival defined as time from date of registration to date of progression or death from any cause.

Secondary outcome measure	
Progression-free survival at 1 year	59% (95% CI: 42-84%)
Progression-free survival at 2 years	36% (95% CI: 21-63%)

1 and 5 year overall survival defined as the time from date of registration to the date of death from any cause.

Secondary outcome measure	
Overall survival at 1 year	86% (95% CI: 73-100%)
Overall survival at 5 years	67% (95% CI: 49-90%)

Adverse Events

Adverse Events by Category

Adverse Event	Related	Unrelated
Blood and lymphatic system disorders	3 (2)	0 (0)
Cardiac disorders	0 (0)	3 (2)
Eye disorders	0 (0)	1 (1)
Gastrointestinal disorders	48 (13)	14 (7)
General disorders and administration site conditions	13 (6)	15 (10)
Immune system disorders	0 (0)	1 (1)
Infections and infestations	17 (10)	4 (2)
Injury, poisoning and procedural complications	0 (0)	2 (2)
Investigations	27 (5)	6 (5)
Metabolism and nutrition disorders	6 (3)	5 (4)
Musculoskeletal and connective tissue disorders	7 (2)	8 (5)
Nervous system disorders	1 (1)	16 (9)
Psychiatric disorders	0 (0)	6 (5)
Renal and urinary disorders	1 (1)	1 (1)
Respiratory, thoracic and mediastinal disorders	4 (2)	19 (8)
Skin and subcutaneous tissue disorders	5 (4)	8 (4)
Vascular disorders	1 (1)	3 (2)

Note: Data are # occurrences (# patients affected)

Adverse Events by Event

Adverse Event	Related	Unrelated
Abdominal pain	3 (3)	3 (2)
Alanine aminotransferase increased	4 (2)	0 (0)
Alkaline phosphatase increased	1 (1)	0 (0)
Allergic reaction	0 (0)	1 (1)
Anal hemorrhage	0 (0)	1 (1)
Anemia	2 (1)	0 (0)
Anorexia	2 (2)	2 (2)
Anxiety	0 (0)	1 (1)
Arthralgia	2 (2)	2 (2)
Aspartate aminotransferase increased	4 (2)	0 (0)
Back pain	1 (1)	2 (2)
Bloating	1 (1)	0 (0)
Blood bilirubin increased	0 (0)	2 (1)
Bruising	0 (0)	1 (1)
Chest pain - cardiac	0 (0)	2 (1)
Colitis	2 (1)	0 (0)
Constipation	8 (5)	4 (3)
Cough	1 (1)	5 (4)
Dehydration	0 (0)	1 (1)
Depression	0 (0)	2 (2)
Diarrhea	15 (7)	0 (0)
Dizziness	0 (0)	3 (3)
Dry skin	0 (0)	1 (1)
Dysgeusia	0 (0)	2 (1)
Dyspepsia	1 (1)	1 (1)
Dyspnea	1 (1)	3 (3)
Edema limbs	0 (0)	2 (2)
Epistaxis	1 (1)	9 (3)
Erythema multiforme	1 (1)	0 (0)
Fall	0 (0)	1 (1)
Fatigue	8 (6)	2 (2)
Febrile neutropenia	1 (1)	0 (0)
Fever	4 (2)	2 (2)
Flank pain	2 (1)	0 (0)
Flatulence	5 (3)	0 (0)
Flu like symptoms	1 (1)	5 (3)
Gastroesophageal reflux disease	0 (0)	1 (1)
Gastrointestinal disorders - Other, barretts oesophagus	0 (0)	1 (1)
Gastrointestinal disorders - Other, tongue ulcer	1 (1)	0 (0)
General disorders and administration site conditions - Other, common cold	0 (0)	1 (1)
General disorders and administration site conditions - Other, influenza b positive	0 (0)	1 (1)
Gum infection	1 (1)	0 (0)
Headache	0 (0)	9 (5)

Adverse Events by Event *(continued)*

Adverse Event	Related	Unrelated
Hypertension	0 (0)	2 (1)
Hyperuricemia	4 (2)	1 (1)
Hypoglycemia	0 (0)	1 (1)
Hypotension	0 (0)	1 (1)
Hypoxia	1 (1)	0 (0)
Infections and infestations - Other, candida on mouth swab	1 (1)	0 (0)
Infections and infestations - Other, coryzal symptoms	2 (1)	0 (0)
Infections and infestations - Other, osteomylitis	0 (0)	1 (1)
Infections and infestations - Other, possible pneumonitis	1 (1)	0 (0)
Insomnia	0 (0)	3 (3)
Investigations - Other, low mood	0 (0)	1 (1)
Lethargy	0 (0)	2 (2)
Lung infection	5 (5)	0 (0)
Mucosal infection	0 (0)	1 (1)
Mucositis oral	2 (1)	0 (0)
Myalgia	2 (1)	1 (1)
Nausea	6 (5)	1 (1)
Neck pain	0 (0)	1 (1)
Nervous system disorders - Other, ageusia - loss of taste	1 (1)	0 (0)
Neutrophil count decreased	17 (2)	1 (1)
Oral pain	0 (0)	1 (1)
Pain	0 (0)	2 (2)
Pain in extremity	0 (0)	2 (2)
Platelet count decreased	1 (1)	0 (0)
Rash acneiform	0 (0)	1 (1)
Rash maculo-papular	3 (2)	0 (0)
Renal and urinary disorders - Other, dysurea	1 (1)	0 (0)
Respiratory, thoracic and mediastinal disorders - Other, aspergillus fumigatus	0 (0)	1 (1)
Respiratory, thoracic and mediastinal disorders - Other, breathless on exertion	0 (0)	1 (1)
Sinus tachycardia	0 (0)	1 (1)
Skin and subcutaneous tissue disorders - Other, acne - rosacea	0 (0)	1 (1)
Skin and subcutaneous tissue disorders - Other, eczema	1 (1)	0 (0)
Skin and subcutaneous tissue disorders - Other, inflammatory eczema	0 (0)	1 (1)
Skin and subcutaneous tissue disorders - Other, rash in groin	0 (0)	1 (1)
Skin and subcutaneous tissue disorders - Other, rash on face	0 (0)	1 (1)
Skin and subcutaneous tissue disorders - Other, rash on legs	0 (0)	2 (2)
Skin infection	2 (2)	0 (0)
Soft tissue infection	1 (1)	0 (0)
Stomach pain	2 (2)	0 (0)
Upper respiratory infection	3 (2)	1 (1)
Urinary retention	0 (0)	1 (1)
Urinary tract infection	1 (1)	0 (0)
Vasculitis	1 (1)	0 (0)
Vomiting	2 (2)	1 (1)

Adverse Events by Event (continued)

Adverse Event	Related	Unrelated
Watering eyes	0 (0)	1 (1)
Weight loss	0 (0)	2 (2)
Wound infection	0 (0)	1 (1)

Note: Data are # occurrences (# patients affected)

Serious Adverse Events

Fatal/Life Threatening Serious Adverse Events

	Expected		Unexpected	
Serious Adverse Event	**Related**	**Unrelated**	**Related**	**Unrelated**
Colitis	1 (1)	0 (0)	0 (0)	0 (0)
Febrile neutropenia	1 (1)	0 (0)	0 (0)	0 (0)
Gastrointestinal disorders - Other, acute peritonitis	0 (0)	0 (0)	0 (0)	1 (1)
Respiratory, thoracic and mediastinal disorders - Other, pulmonary infarction	0 (0)	0 (0)	0 (0)	1 (1)

Note:

Data are # occurrences (# patients affected)

Event term reported is event that prompted reporting as SAE

Non-Life Threatening Serious Adverse Events

	Expected		Unexpected	
Serious Adverse Event	**Related**	**Unrelated**	**Related**	**Unrelated**
Abdominal pain	1 (1)	0 (0)	0 (0)	0 (0)
Blood bilirubin increased	0 (0)	0 (0)	0 (0)	1 (1)
Cardiac disorders - Other, pulmonary edema	0 (0)	0 (0)	0 (0)	1 (1)
Colitis	2 (1)	0 (0)	0 (0)	0 (0)
Diarrhea	2 (2)	0 (0)	0 (0)	0 (0)
Dyspnea	1 (1)	0 (0)	0 (0)	0 (0)
Febrile neutropenia	1 (1)	0 (0)	0 (0)	0 (0)
Fever	3 (1)	0 (0)	0 (0)	2 (2)
Infections and infestations - Other, chest infection	1 (1)	0 (0)	0 (0)	0 (0)
Infections and infestations - Other, osteomyelitis	0 (0)	0 (0)	0 (0)	2 (1)
Pneumonitis	2 (2)	0 (0)	0 (0)	0 (0)
Respiratory, thoracic and mediastinal disorders - Other, pneumonia	0 (0)	0 (0)	0 (0)	2 (2)
Skin and subcutaneous tissue disorders - Other, rash	1 (1)	0 (0)	0 (0)	0 (0)
Vomiting	1 (1)	0 (0)	0 (0)	0 (0)

Note:

Data are # occurrences (# patients affected)

Event term reported is event that prompted reporting as SAE